## Contents

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Targets</td>
<td>1</td>
</tr>
<tr>
<td>Christina M. Annunziata and Phillip A. Dennis</td>
<td></td>
</tr>
<tr>
<td>Preclinical Screening for New Anticancer Agents</td>
<td>23</td>
</tr>
<tr>
<td>Angelika M. Burger and Heinz-Herbert Fiebig</td>
<td></td>
</tr>
<tr>
<td>Natural Product Screening</td>
<td>39</td>
</tr>
<tr>
<td>Tawnya C. McKee, Albert W.W. Van Wyk, and Emily L. Whitson</td>
<td></td>
</tr>
<tr>
<td>Defining the Starting Dose: Should It Be mg/kg, mg/m², or Fixed?</td>
<td>69</td>
</tr>
<tr>
<td>Bo Gao, Heinz-Josef Klumpen, and Howard Gurney</td>
<td></td>
</tr>
<tr>
<td>Phase 0 Trials in Oncology</td>
<td>89</td>
</tr>
<tr>
<td>Shivaani Kummar and James H. Doroshow</td>
<td></td>
</tr>
<tr>
<td>Phase I Trials in Oncology: Design and Endpoints</td>
<td>99</td>
</tr>
<tr>
<td>Hilary Glen and Jim Cassidy</td>
<td></td>
</tr>
<tr>
<td>Quantitative Analytical Methods: Development and Clinical Considerations</td>
<td>107</td>
</tr>
<tr>
<td>Erin R. Gardner</td>
<td></td>
</tr>
<tr>
<td>Validation and Control of Bioanalytical Methods</td>
<td>117</td>
</tr>
<tr>
<td>H. Thomas Karnes and Kumar A. Shah</td>
<td></td>
</tr>
<tr>
<td>Anticancer Clinical Pharmacology Overview</td>
<td>141</td>
</tr>
<tr>
<td>Uday B. Dandamudi, Andrew Beelen, and Lionel D. Lewis</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetic Modeling</td>
<td>159</td>
</tr>
<tr>
<td>Jing Li and Michelle A. Rudek</td>
<td></td>
</tr>
<tr>
<td>Pharmacometrics</td>
<td>173</td>
</tr>
<tr>
<td>Satjit S. Brar and Joga Gobburu</td>
<td></td>
</tr>
<tr>
<td>Pharmacodynamic Modeling</td>
<td>193</td>
</tr>
<tr>
<td>Kenneth S. Bauer and Fatemeh Tavakkoli</td>
<td></td>
</tr>
<tr>
<td>Protein Binding</td>
<td>209</td>
</tr>
<tr>
<td>Alex Sparreboom and Walter J. Loos</td>
<td></td>
</tr>
<tr>
<td>Metabolism (Non-CYP Enzymes)</td>
<td>229</td>
</tr>
<tr>
<td>David Jamieson, Sally A. Coulthard, and Alan V. Boddy</td>
<td></td>
</tr>
</tbody>
</table>
Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms .......... 255
Jai N. Patel and Howard L. McLeod

Cytochrome P450 ........................................................................................................... 273
Yuichi Ando

Polymorphisms in Genes of Drug Targets and Metabolism ........................................ 289
Pierre Bohanes and Heinz-Josef Lenz

DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance ............ 333
Eddie Reed, Teri L. Larkins, Cindy H. Chau, and William D. Figg

Drug Interactions ............................................................................................................. 351
Laurent P. Rivory

ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition ........ 373
Paul R. Massey, Tito Fojo, and Susan E. Bates

Solute Carriers ................................................................................................................ 401
Richard H. Ho and Richard B. Kim

High-Throughput Platforms in Drug Metabolism and Transport Pharmacogenetics .......... 443
Bevin C. English, Emily D. Richardson, and Tristan M. Sissung

Intrathecal Administration ............................................................................................. 457
Lindsay B. Kilburn, Stacey Berg, and Susan M. Blaney

Microdialysis ................................................................................................................... 477
Austin J. Combest and William C. Zamboni

Regional Drug Delivery for Inoperable Pulmonary Malignancies ............................. 499
David S. Schrump

Blood–Brain Barrier and CNS Malignancy ................................................................. 519
Ani Balmanoukian and Stuart A. Grossman

Radiation and Altering Clinical Pharmacology ......................................................... 541
DeeDee Smart and Kevin Camphausen

Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment ........ 553
Ravi A. Madan, Theresa A. Ferrara, and James L. Gulley

Recombinant Immunotoxins ........................................................................................ 569
Robert J. Kreitman

Monoclonal Antibodies ................................................................................................ 585
Shuang Bai, Rong Deng, Hong Xiang, Manish Gupta, Luna Musib, Banmeet Anand, and Bert Lum

Clinical Pharmacology in Pediatrics ............................................................................ 625
Michael Tagen and Clinton F. Stewart

Clinical Pharmacology in the Older Adult .................................................................. 661
Patricia W. Slattum and Jürgen Venitz

Organ Dysfunction Trials: Background, Historical Barriers, Progress in Overcoming Barriers, and Suggestions for Future Trials ............................................ 673
Shivaani Kummar, S. Percy Ivy, and Pamela Jo Harris
Drug Formulations: How these Affects Anticancer Drug ....................................................... 689
Jurjen S. Lagas, Bastiaan Nuijen, Jan H.M. Schellens, and Jos H. Beijnen

Nanotechnology in Cancer ......................................................................................................... 703
Margit M. Janát-Amsbury and You Han Bae

Imaging in Drug Development .................................................................................................. 731
Karen A. Kurdziel, Esther Mena, Stephen Adler, and Peter Choyke

Atiqur Rahman

The Role of Phase III Trials in Modern Drug Development ..................................................... 763
Janet E. Murphy, Lecia V. Sequist, and Bruce A. Chabner

Clinical Trial Designs for Approval of New Anticancer Agents .............................................. 785
Manpreet K. Chadha and Daniel D. Von Hoff

Clinical Pharmacogenetics ......................................................................................................... 803
Kamakshi Sachidanandam and Jill M. Kolesar

Index ............................................................................................................................................. 823
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
Rudek, M.A.; Chau, C.H.; Figg, W.; McLeod, H.L. (Eds.)
2014, IX, 836 p. 145 illus., 46 illus. in color., Hardcover
ISBN: 978-1-4614-9134-7
A product of Humana Press